Lucid Diagnostics Completes Successful Common Stock Offering
Lucid Diagnostics Inc. (NASDAQ: LUCD), a company dedicated to cancer prevention through medical diagnostics, has successfully closed its underwritten public offering. This significant step marks the company's continued commitment to enhancing its operations and providing essential healthcare solutions.
In this recent offering, Lucid has made available 14,375,000 shares of common stock, which included 1,875,000 shares under the underwriters' option to purchase additional shares. The public offering price was set at $1.20 per share. With these efforts, Lucid aims to bolster its financial resources for future growth and development.
The total net proceeds from this offering are projected to be around $16.1 million. This will be utilized primarily for working capital and general corporate purposes, further solidifying the company’s foundation and supporting its mission to provide cutting-edge cancer prevention measures.
Canaccord Genuity LLC served as the sole bookrunner for this offering, with Maxim Group LLC acting as co-manager. This collaborative effort showcases the confidence and strategic partnerships that Lucid Diagnostics is fostering within the industry.
The securities involved in this offering were made available under a shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission. A prospectus supplement accompanying the offering is available for interested parties, offering transparency and information regarding the stock offerings.
About Lucid Diagnostics
Lucid Diagnostics Inc. is recognized as an innovative leader in the cancer prevention sector, operating as a subsidiary of PAVmed Inc. (NASDAQ: PAVM). The company is dedicated to addressing the needs of patients suffering from gastroesophageal reflux disease (GERD), a serious condition that predisposes individuals to esophageal cancer risks.
Lucid's unique approach features the EsoGuard® Esophageal DNA Test and the EsoCheck® esophageal cell collection device. Both tools are designed to facilitate early detection of esophageal precancer, aiming to prevent cancerous developments. The procedures involved are noninvasive and are performed within a clinic, making this technology accessible to many patients facing these health risks.
As Lucid continues to expand its reach, the company is well-positioned for future developments, transforming the landscape of cancer diagnostics and prevention. With the newly raised funds, Lucid aims to further enhance its product lineup and continue advocating for widespread cancer screening to improve patient outcomes.
For more information on Lucid Diagnostics and their integral service offerings, including further details on their innovative products, reviews of patient procedures, and corporate updates, visit the company’s official website.
Frequently Asked Questions
What is the purpose of Lucid Diagnostics' recent stock offering?
The recent stock offering aims to raise funds for working capital and general corporate purposes, supporting the company’s growth in cancer prevention.
How many shares were offered in the public offering?
Lucid Diagnostics offered a total of 14,375,000 shares of its common stock to the public.
What is the expected net proceeds from the offering?
The total net proceeds are expected to be approximately $16.1 million after deducting expenses.
Who managed the stock offering?
Canaccord Genuity LLC acted as the sole bookrunner, with Maxim Group LLC serving as co-manager for the offering.
What products does Lucid Diagnostics provide for cancer prevention?
Lucid provides the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device for early detection of esophageal precancer and cancer.
